 |
| Original Article |
| Immunotherapy for murine K1735 melanoma: Combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators |
|
| Isabelle Peter1,a, Michael Nawrath2,a, Jivko Kamarashev3, Bernhard Odermatt4, Anna Mezzacasa1 and Silvio Hemmi1 |
|
1Institute of Molecular Biology, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
2Institute of Medical Virology, University of Zürich, Gloriastrasse 30, CH-8028 Zürich, Switzerland
3Department of Dermatology, University Hospital, Gloriastrasse 31, CH-8091 Zürich, Switzerland
4Department of Experimental Immunology, University Hospital, Gloriastrasse 31, CH-8091 Zürich, Switzerland
|
Correspondence to: Dr Silvio Hemmi, Institute of Molecular Biology, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. E-mail: hemmi@molbio.unizh.ch | |
aBoth authors contributed equally to this work. |
|
| Abstract |
| We have constructed and tested five recombinant adenoviruses (Ads) that express a variety of immunomodulators, including CD40 ligand (CD40L), a potent costimulator of several components of the immune system. We demonstrate that CD40L expressed from Ad in K1735 mouse melanoma cells leads to a strong reduction in tumorigenicity and to efficient protective immunity in a vaccination setting. Subsequently, using a therapeutic approach, we found that local, intratumoral coinjection of CD40L- and IL-2-expressing Ads was superior to any other agents tested and resulted in an at least 1.9-fold increase in mean survival time, in contrast to systemic application of recombinant CD40L or GM-CSF proteins, which had no significant effects. When using vaccination as a therapeutic approach, the combinations of CD40L plus IL-2 or GM-CSF plus IL-2 from Ad gave rise to an extended (2.8-fold) increase in mean survival time. A detailed analysis of immune cells present within regressing tumors indicated that mainly CD4+ and CD8+ T cells, and to a lesser extent dendritic cells, infiltrated the tumor mass, but not NK cells, macrophages, or granulocytes. These results propose that a combination of CD40L plus IL-2 has an improved efficacy over the use of single agents when applied for direct in situ therapy or vaccination therapy. Cancer Gene Therapy (2002) 9, 597-605 doi:10.1038/sj.cgt.7700475 |
|
| Keywords |
| melanoma; immunotherapy; adenovirus; CD40L; cytokines; K1735 |
|
|
|
|
| Received 10 April 2002 |
|
| July 2002, Volume 9, Number 7, Pages 597-605 |
| Table of contents Previous Abstract Next Full text PDF |
|
